<doc>
  <docmeta id="113s627is">
    <bill congress="113" type="s" number="627" version="is"/>
    <revision size="33286" annotations="0" id="9" commit-time="2013-08-29T22:29:54Z" status="complete" committer="mbohmer" doc="113s627is/9.xml">
      <description description="Markup copied from completed documents">Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 S627 IS: Medical Innovation Prize Fund Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2013-03-20</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 627</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130320">March 20, 2013</action-date>
			<action-desc>
        <sponsor name-id="S313">Mr. Sanders</sponsor> introduced
			 the following bill; which was read twice and referred to the
			 <committee-name committee-id="SSHR00">Committee on Health, Education, Labor,
			 and Pensions</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To provide incentives for investment in research and
		  development for new medicines, to enhance access to new medicines, and for
		  other purposes.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one">
      <enum>1.</enum>
      <header>Short
			 title</header>
      <text display-inline="no-display-inline">This Act may be cited as
			 the <quote>
          <short-title>Medical Innovation Prize Fund
			 Act</short-title>
        </quote>.</text>
		</section>
    <section id="idB59CCA7C2E3C47B583F2BC606B6D449A">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="0001" entity-type="federal-body">Congress</cato:entity-ref> makes the following
			 findings:</text>
			<paragraph id="id9BE7E08F01604AC39FBBC141A225CA37">
        <enum>(1)</enum>
        <text display-inline="yes-display-inline">The development of new medicines and
			 vaccines is necessary to improve health care outcomes.</text>
			</paragraph>
      <paragraph id="id714545F40B194831B081962E440FFF37">
        <enum>(2)</enum>
        <text display-inline="yes-display-inline">Market exclusivity for new products is an
			 expensive, inefficient, and unfair mechanism to reward investments in new
			 products.</text>
			</paragraph>
      <paragraph id="idBDE0F196AE1D4D32A097A3EBDF23BBC1">
        <enum>(3)</enum>
        <text display-inline="yes-display-inline">By de-linking research and development
			 incentives from product prices, and by eliminating legal monopolies to sell
			 products, it is possible to induce investments that are medically more
			 important, procure products at low prices from competitive suppliers, radically
			 lower pricing barriers for access to new medicines, reduce wasteful marketing
			 and research and development activities, and dramatically lower the overall
			 costs of acquiring innovation, while expanding access to that
			 innovation.</text>
			</paragraph>
      <paragraph id="id3ED537E6332D4D87A652912A5B2ED47C">
        <enum>(4)</enum>
        <text display-inline="yes-display-inline">By funding innovation prizes at .55 percent
			 of gross domestic product, the United States would provide more than
			 $86,000,000,000 in rewards for successful innovation in 2012.</text>
			</paragraph>
      <paragraph id="id57CAB2EE841C41B597FFD8733B4D02F1">
        <enum>(5)</enum>
        <text display-inline="yes-display-inline">The development of new medicines benefits
			 from greater sharing of knowledge, data, materials, and technologies.</text>
			</paragraph>
    </section>
    <section id="id51F6A98546164472AB815AEE8C2BFFE8">
      <enum>3.</enum>
      <header>Purpose</header>
      <text display-inline="no-display-inline">It is the purpose of this Act to provide
			 incentives to encourage entities to invest in research and development of new
			 medicines and to share knowledge, data, materials, and technology, through the
			 establishment of a Medical Innovation Prize Fund, while enhancing access to
			 such medicines by eliminating legal monopolies on the manufacture,
			 distribution, and sale of such medicines.</text>
		</section>
    <section id="idAC4F063505AE4B419A14FA0D78F68459">
      <enum>4.</enum>
      <header>Definitions</header>
      <text display-inline="no-display-inline">In this Act:</text>
			<paragraph id="id48F480C6D1CD4E6689EA11CA6CBDB331">
        <enum>(1)</enum>
        <header>Biological
			 product</header>
        <text>The term <term>biological product</term> has the meaning
			 given such term in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Public Health Service Act/s:351" entity-type="act">section 351 of the Public Health Service Act</cato:entity-ref> (<cato:entity-ref value="usc/42/262" entity-type="uscode">42 U.S.C.
			 262</cato:entity-ref>)</cato:entity>.</text>
			</paragraph>
      <paragraph id="IDa0e0bf5f444747d1a73a4a795375488b">
        <enum>(2)</enum>
        <header>Board</header>
        <text>The
			 term <quote>Board</quote> means the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board of Trustees for the Fund for Medical
			 Innovation Prizes</cato:entity-ref> established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:7" entity-type="act">section 7</cato:entity-ref>.</text>
			</paragraph>
      <paragraph id="IDdf9e86b200ec451ba70dcc37aa4c0f34">
        <enum>(3)</enum>
        <header>Drug</header>
        <text>The
			 term <term>drug</term> has the meaning given such term in <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Federal Food, Drug, and Cosmetic Act/s:201" entity-type="act">section 201 of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/321">
              <cato:entity-ref value="usc/21/321" entity-type="uscode">21 U.S.C. 321</cato:entity-ref>
            </external-xref>)</cato:entity>.</text>
			</paragraph>
      <paragraph id="ID0efc3a666a3449719e04b253a6dc2f5c">
        <enum>(4)</enum>
        <header>Fund</header>
        <text>The
			 term <term>Fund</term> means the Fund for Medical Innovation Prizes established
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:6" entity-type="act">section 6</cato:entity-ref>.</text>
			</paragraph>
      <paragraph id="ID588e3245aacb43f080ff70fee5e99d3c">
        <enum>(5)</enum>
        <header>Market
			 clearance</header>
        <text>The term <term>market clearance</term> means the
			 approval of an application under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Federal Food, Drug, and Cosmetic Act/s:505" entity-type="act">section 505 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
              <cato:entity-ref value="usc/21/355" entity-type="uscode">21 U.S.C. 355</cato:entity-ref>
            </external-xref>)</cato:entity> or the approval of a biologics license application
			 under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Public Health Service Act/s:351/ss:a" entity-type="act">subsection (a) of section 351 of the Public Health Service Act</cato:entity-ref> (<cato:entity-ref value="usc/42/262" entity-type="uscode">42 U.S.C.
			 262</cato:entity-ref>)</cato:entity>.</text>
			</paragraph>
    </section>
    <section id="idA2691CB212AF4F31A674B8232411DF32">
      <enum>5.</enum>
      <header>Elimination of
			 exclusive rights to market drugs and biological products</header>
			<subsection id="id4542086738434762813C97763BCB0F47">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text>Notwithstanding <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="usc/35" entity-type="uscode">title 35, United States Code</cato:entity-ref>, relevant
			 provisions of the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Federal Food, Drug, and Cosmetic Act" entity-type="act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref value="usc/21/301/etseq" entity-type="uscode">
              <external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>
            </cato:entity-ref>)</cato:entity>
			 (including amendments made by the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Drug Price Competition and Patent Term Restoration Act of 1984" entity-type="act">Drug Price Competition and Patent Term
			 Restoration Act of 1984</cato:entity-ref> (<external-xref legal-doc="public-law" parsable-cite="pl/98/417">
              <cato:entity-ref value="public-law/98/417" entity-type="public-law">Public Law 98–417</cato:entity-ref>
            </external-xref>; commonly referred to as the
			 <cato:entity-ref value="Hatch-Waxman Act" entity-type="act">
              <term>Hatch-Waxman Act</term>
            </cato:entity-ref>))</cato:entity>, the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003" entity-type="act">Medicare Prescription Drug, Improvement,
			 and Modernization Act of 2003</cato:entity-ref> (<external-xref legal-doc="public-law" parsable-cite="pl/108/173">
              <cato:entity-ref value="public-law/108/173" entity-type="public-law">Public Law 108–173</cato:entity-ref>
            </external-xref>)</cato:entity>, and any other provision of
			 law providing any patent right or exclusive marketing period for any drug,
			 biological product, or manufacturing process for a drug or biological product
			 (such as pediatric extensions under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Federal Food, Drug, and Cosmetic Act/s:505A" entity-type="act">section 505A of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<cato:entity-ref value="usc/21/355a" entity-type="uscode">
              <external-xref legal-doc="usc" parsable-cite="usc/21/355a">21 U.S.C. 355a</external-xref>
            </cato:entity-ref>)</cato:entity> or orphan drug marketing exclusivity under
			 <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:B" entity-type="act">subchapter B of chapter V of such Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/360aa">
              <cato:entity-ref value="usc/21/360aa/etseq" entity-type="uscode">21 U.S.C. 360aa et seq.</cato:entity-ref>
            </external-xref>)</cato:entity>), no person
			 shall have the right to exclusively manufacture, distribute, sell, or use a
			 drug, a biological product, or a manufacturing process for a drug or biological
			 product in interstate commerce, including the exclusive right to rely on health
			 registration data or the 30-month stay-of-effectiveness period for Orange Book
			 patents under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j" entity-type="act">section 505(j) of such Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
              <cato:entity-ref value="usc/21/355/j" entity-type="uscode">21 U.S.C. 355(j)</cato:entity-ref>
            </external-xref>)</cato:entity>.</text>
			</subsection>
      <subsection id="id26FCFC726739485BB4BCC9433FF15889">
        <enum>(b)</enum>
        <header>Remuneration</header>
        <text>A
			 person that is eligible for prize payments from the Fund as provided for in
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:9" entity-type="act">sections 9</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:10" entity-type="act">10</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:11" entity-type="act">11</cato:entity-ref> shall receive such payments—</text>
				<paragraph id="ID5c47bc49188e48e6aa134ffdd4724958">
          <enum>(1)</enum>
          <text>in lieu of any
			 remuneration the person would have otherwise received for the exclusive
			 marketing, distribution, sale, or use of a drug, biological product, or
			 manufacturing process for a drug or biological product but for the application
			 of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:5/ss:a" entity-type="act">subsection (a)</cato:entity-ref>; and</text>
				</paragraph>
        <paragraph id="ID3f38317d248a46fb86cfc32eef4fb6d1">
          <enum>(2)</enum>
          <text>in addition to
			 any other remuneration that such person receives by reason of the nonexclusive
			 marketing, distribution, sale, or use of the drug, biological product, or
			 manufacturing process for a drug or biological product.</text>
				</paragraph>
      </subsection>
      <subsection id="id1EEAA35776814DFE84D5F91E5B945091">
        <enum>(c)</enum>
        <header>Application</header>
        <text>This
			 section shall apply only with respect to the marketing, distribution, sale, or
			 use of a drug, a biological product, or a manufacturing process for a drug or
			 biological product that occurs on or after October 1, 2014.</text>
			</subsection>
    </section>
    <section id="id2F930875A2E149278138150494AC13A5">
      <enum>6.</enum>
      <header>Fund for medical
			 innovation prizes</header>
			<subsection id="id6CAB3071EDA742E29A74FAB381A95B11">
        <enum>(a)</enum>
        <header>Establishment</header>
        <text>There
			 is hereby established in the Treasury of the United States a revolving fund to
			 be known as the <term>Fund for Medical Innovation Prizes</term>, which shall
			 consist of amounts appropriated to the Fund and amounts credited to the Fund
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:6/ss:c" entity-type="act">subsection (c)</cato:entity-ref>.</text>
			</subsection>
      <subsection id="id2EE2CDC3798D47C7AC53E740E10B975E">
        <enum>(b)</enum>
        <header>Availability of
			 funds</header>
        <text>Amounts in the Fund shall be available to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref>,
			 subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:17/ss:c" entity-type="act">section 17(c)</cato:entity-ref>, for the purpose of carrying out this Act.</text>
			</subsection>
      <subsection id="idE936F2E332E8424B83C792679D151276">
        <enum>(c)</enum>
        <header>Amounts
			 credited to the Fund</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="2000" entity-type="federal-body">Secretary of the Treasury</cato:entity-ref> shall credit
			 to the Fund the interest on, and the proceeds from sale or redemption of,
			 obligations held in the Fund.</text>
			</subsection>
    </section>
    <section id="id697AB1A112C242E7B8B346E3E342DB15">
      <enum>7.</enum>
      <header>Board of
			 trustees for the Fund</header>
			<subsection id="idE9C7FB0536A14498B1556800B9DF9C46">
        <enum>(a)</enum>
        <header>Establishment</header>
        <text>There
			 is hereby established (as a permanent, independent establishment in the
			 executive branch) a <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board of Trustees for the Fund for Medical Innovation
			 Prizes</cato:entity-ref>.</text>
			</subsection>
      <subsection id="idDC0D1D20FF93491AB3A99F9F876DAB3F">
        <enum>(b)</enum>
        <header>Membership</header>
        <text>The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall be composed of 13 members, including—</text>
				<paragraph id="ID0541197ae0b3421282cf60fa917903cf">
          <enum>(1)</enum>
          <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7530" entity-type="federal-body">Administrator
			 of the Centers for Medicare &amp; Medicaid Services</cato:entity-ref>;</text>
				</paragraph>
        <paragraph id="IDc6745e95cc544804ac1206e2683776ec">
          <enum>(2)</enum>
          <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Commissioner of Food and Drugs</cato:entity-ref>;</text>
				</paragraph>
        <paragraph id="ID637dbb695fa74920b1383302c4dd7e6e">
          <enum>(3)</enum>
          <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of the National Institutes of
				Health</cato:entity-ref>;</text>
				</paragraph>
        <paragraph id="IDab911002e137473294ac0a165587e4e8">
          <enum>(4)</enum>
          <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7523" entity-type="federal-body">Director of
			 the Centers for Disease Control and Prevention</cato:entity-ref>; and</text>
				</paragraph>
        <paragraph id="IDb6556662d2de4cf9ae20efed45103cb5">
          <enum>(5)</enum>
          <text>9 individuals to
			 be appointed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1100" entity-type="federal-body">President</cato:entity-ref>, with the advice and consent of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="0010" entity-type="federal-body">Senate</cato:entity-ref>, of
			 which—</text>
					<subparagraph id="ID60a8379b41a14560897cebab4a902f30">
            <enum>(A)</enum>
            <text>2 shall be
			 representatives of businesses that provide health insurance to
			 employees;</text>
					</subparagraph>
          <subparagraph id="ID8c53b145a62b424f8c22f9bdea2b64e5">
            <enum>(B)</enum>
            <text>2 shall be
			 representatives of entities that provide health insurance and contribute to the
			 co-funding of the Fund for Medical Innovation Prizes under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:17" entity-type="act">section 17</cato:entity-ref>;</text>
					</subparagraph>
          <subparagraph id="ID15ee23a6fa784e64bfe65e45defb8ae9">
            <enum>(C)</enum>
            <text>2 shall be
			 representatives of the medical research and development sector, including at
			 least 1 representative of the nonprofit private medical research and
			 development sector; and</text>
					</subparagraph>
          <subparagraph id="ID5ce02b7554684247a64cbe42ee559511">
            <enum>(D)</enum>
            <text>3 shall be
			 representatives of consumer and patient interests, including at least one
			 representative of patients suffering from orphan diseases.</text>
					</subparagraph>
        </paragraph>
      </subsection>
      <subsection id="id322A2924BF6F4F539D139319331788BA">
        <enum>(c)</enum>
        <header>Terms</header>
				<paragraph id="id89F0057B753D48D493FAE108442F66DB">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text>Except as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:7/ss:c/p:2" entity-type="act">paragraph (2)</cato:entity-ref>, each member
			 appointed to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:7/ss:b/p:5" entity-type="act">subsection (b)(5)</cato:entity-ref> shall be appointed for a term of
			 4 years.</text>
				</paragraph>
        <paragraph id="IDf5e6c17ce4af4d0ebf73137911b9e8b6">
          <enum>(2)</enum>
          <header>Terms of
			 initial appointees</header>
          <text>As designated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="1100" entity-type="federal-body">President</cato:entity-ref> at the time of
			 appointment, of the members first appointed to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:7/ss:b/p:5" entity-type="act">subsection
			 (b)(5)</cato:entity-ref>—</text>
					<subparagraph id="IDaf7f98d767524ead9103940cfc4f0ede">
            <enum>(A)</enum>
            <text>5 members shall
			 be appointed for a term of 4 years; and</text>
					</subparagraph>
          <subparagraph id="IDc759e6f24bb44f8a864383a12563ae5e">
            <enum>(B)</enum>
            <text>4 members shall
			 be appointed for a term of 2 years.</text>
					</subparagraph>
        </paragraph>
      </subsection>
      <subsection id="idE29A461E4D814B7FBC22D28655FDCFAD">
        <enum>(d)</enum>
        <header>Vacancies</header>
        <text>Any
			 member of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> appointed to fill a vacancy occurring before the expiration
			 of the term for which the member's predecessor was appointed shall be appointed
			 only for the remainder of that term. A member of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> may serve after the
			 expiration of that member's term until a successor has taken office.</text>
			</subsection>
      <subsection id="ID4e46761daf41482fae8d78780590396e">
        <enum>(e)</enum>
        <header>Compensation
			 and travel expenses</header>
				<paragraph id="ID703675768ab14635a00560b8fd292aee">
          <enum>(1)</enum>
          <header>Compensation</header>
          <text>Members
			 of the Board shall each be paid not less than the daily equivalent of level IV
			 of the Executive Schedule for each day (including travel time) during which
			 they are engaged in the actual performance of the duties of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref>.</text>
				</paragraph>
        <paragraph id="IDcad78108544a4c62abc2f2ff4b1bff53">
          <enum>(2)</enum>
          <header>Travel
			 expenses</header>
          <text>Each member of the Board shall receive travel expenses,
			 including per diem in lieu of subsistence, in accordance with applicable
			 provisions under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="usc-chapter/5/57/I" entity-type="uscode">subchapter I of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/57">chapter 57</external-xref> of title 5, United States
			 Code</cato:entity-ref>.</text>
				</paragraph>
      </subsection>
      <subsection id="IDcf37164d52f043e1bece9895f830e685">
        <enum>(f)</enum>
        <header>Chairperson;
			 Officers</header>
        <text>The members of the Board shall elect a <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Chairperson of the Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Chairperson</cato:entity-ref> and
			 any other officers of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref>. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Chairperson of the Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Chairperson</cato:entity-ref> and any such officers shall be
			 elected for a term of 2 years.</text>
			</subsection>
      <subsection id="IDbcc4fb53f1064d5ba81def7fc6de1d6d">
        <enum>(g)</enum>
        <header>Staff</header>
        <text>The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> may appoint and fix the pay of such additional personnel as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref>
			 considers appropriate. The staff of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall be appointed subject to the
			 provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="usc/5" entity-type="uscode">title 5, United States Code</cato:entity-ref>, governing appointments in the
			 competitive service, and shall be paid in accordance with the provisions of
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="usc-chapter/5/51" entity-type="uscode">chapter 51</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="usc-chapter/5/53/III" entity-type="uscode">subchapter III of chapter 53 of such title</cato:entity-ref> relating to
			 classification and General Schedule pay rates.</text>
			</subsection>
      <subsection id="ID690c9454b38f42f0b81e2176c6822c61">
        <enum>(h)</enum>
        <header>Experts and
			 consultants</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> may procure temporary and intermittent
			 services under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="usc/5/3109/b" entity-type="uscode">
            <external-xref legal-doc="usc" parsable-cite="usc/5/3109">section 3109(b)</external-xref> of title 5, United States Code</cato:entity-ref>.</text>
			</subsection>
    </section>
    <section id="id185970A0A0164CB089AF828E0351B508">
      <enum>8.</enum>
      <header>Powers and
			 duties of the Board</header>
			<subsection id="id7106D158CC534660922EC29A24A8DCDA">
        <enum>(a)</enum>
        <header>Duties</header>
        <text>The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall—</text>
				<paragraph id="ID177301bd39c6439287496f714810419a">
          <enum>(1)</enum>
          <text>award prize
			 payments for medical innovation in accordance with this Act; and</text>
				</paragraph>
        <paragraph id="ID1cc2d046b7124196b9f125ae36a638e8">
          <enum>(2)</enum>
          <text>submit a report
			 to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="0001" entity-type="federal-body">Congress</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:16" entity-type="act">section 16</cato:entity-ref>.</text>
				</paragraph>
      </subsection>
      <subsection id="idA37710A2C8BA4BA5A44A559452C387AD">
        <enum>(b)</enum>
        <header>Powers of
			 Board</header>
				<paragraph id="idDBAC24FAE7284F95AD44382EBBE28DFE">
          <enum>(1)</enum>
          <header>Hearings and
			 sessions</header>
					<subparagraph id="id1DC38CC86F8E40FF82ED5AC5D49622E7">
            <enum>(A)</enum>
            <header>In
			 general</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> may, for the purpose of carrying out this Act,
			 hold hearings, sit and act at times and places, take testimony, and receive
			 evidence as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> considers appropriate.</text>
					</subparagraph>
          <subparagraph id="ID27c72a1317f848bf91999ca1ae8e35c8">
            <enum>(B)</enum>
            <header>First
			 meeting</header>
            <text>Not later than 30 days after the initial members of the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> are appointed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:7/ss:b/p:5" entity-type="act">section 7(b)(5)</cato:entity-ref> and confirmed, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall
			 conduct its first meeting.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="id5BE9B8C680C14335BF33C5F1A8C6D860">
          <enum>(2)</enum>
          <header>Policies and
			 procedures</header>
					<subparagraph id="id055DAB0F697C4AF1B0BECC3F38A54943">
            <enum>(A)</enum>
            <header>In
			 general</header>
            <text>Not later than 1 year after the initial members of the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> are appointed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:7/ss:b/p:5" entity-type="act">section 7(b)(5)</cato:entity-ref> and confirmed, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall
			 establish such policies and procedures as may be appropriate to carry out this
			 Act.</text>
					</subparagraph>
          <subparagraph id="id94D3F7387BC14E12845B3E6C1A910542">
            <enum>(B)</enum>
            <header>Majority
			 vote</header>
            <text>The policies and procedures of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall require that
			 any determination of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> be made by not less than a majority vote of the
			 members of the Board.</text>
					</subparagraph>
          <subparagraph id="IDf1d1d34bcd594082831dd67c69108755">
            <enum>(C)</enum>
            <header>Administrative
			 procedures</header>
            <text>The policies and procedures of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall comply
			 with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="usc-chapter/5/5/II" entity-type="uscode">subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/5">chapter 5</external-xref> of title 5, United States Code</cato:entity-ref>.</text>
					</subparagraph>
          <subparagraph id="ID9c1e9b720295479eb387218d65a46555">
            <enum>(D)</enum>
            <header>Transparency</header>
            <text>The
			 policies and procedures of the Board shall—</text>
						<clause id="ID3c8b9a06923b4f409fca221307104dfd">
              <enum>(i)</enum>
              <text>comply with
			 
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="usc/5/552" entity-type="uscode">sections <external-xref legal-doc="usc" parsable-cite="usc/5/552">552</external-xref>
                  </cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="usc/5/552a" entity-type="uscode">
                    <external-xref legal-doc="usc" parsable-cite="usc/5/552b">552b</external-xref> of title 5, United States Code</cato:entity-ref> (commonly referred to as
			 the <term>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Freedom of Information Act" entity-type="act">Freedom of Information Act</cato:entity-ref>
                  </term> and the <term>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" value="Government in the Sunshine Act" entity-type="act">Government in the
			 Sunshine Act</cato:entity-ref>
                  </term>, respectively); and</text>
						</clause>
            <clause id="ID92e107e8f0da439e93a501f486bf803a">
              <enum>(ii)</enum>
              <text>ensure that the
			 proceedings and deliberations of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> are transparent and are supported by
			 a description of the methods, data sources, assumptions, outcomes, and related
			 information that will allow the public to understand how the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> reaches its
			 criteria-setting and award decisions.</text>
						</clause>
          </subparagraph>
        </paragraph>
        <paragraph id="id403A03CF7F9046A1879C9F2CD0D7FA5B">
          <enum>(3)</enum>
          <header>Expert advisory
			 committees</header>
          <text>To assist the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> in carrying out this Act, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall establish independent expert advisory committees, including
			 committees on the following:</text>
					<subparagraph id="ID81180be7472447ca848bd8b792bd65b6">
            <enum>(A)</enum>
            <text>Economic
			 evaluation of therapeutic benefits.</text>
					</subparagraph>
          <subparagraph id="IDeec6a5a7333e4f1b96578c4849c7afe1">
            <enum>(B)</enum>
            <text>Business models
			 and incentive structures for innovation.</text>
					</subparagraph>
          <subparagraph id="ID89c3af45b73149b583940abd0e431325">
            <enum>(C)</enum>
            <text>Research and
			 development priorities.</text>
					</subparagraph>
          <subparagraph id="IDca12ea2f676d438fabd3f322335f2ce4">
            <enum>(D)</enum>
            <text>Orphan
			 diseases.</text>
					</subparagraph>
          <subparagraph id="ID6c1a5e8ffbf944b4baf7dac451bad08d">
            <enum>(E)</enum>
            <text>Financial control
			 and auditing.</text>
					</subparagraph>
          <subparagraph id="IDfc313de07dd94f01a54f2d972a04ba66">
            <enum>(F)</enum>
            <text>Open source
			 biomedical science.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="IDe225064b5d4d43ad844c5bd3828cbefa">
          <enum>(4)</enum>
          <header>Powers of
			 members and agents</header>
          <text>Any member or agent of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> may, if
			 authorized by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref>, take any action which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> is authorized to take
			 under this Act.</text>
				</paragraph>
        <paragraph id="ID6e5eddbb200b4e6d92a8bcb01ffd62eb">
          <enum>(5)</enum>
          <header>Mails</header>
          <text>The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> may use the United States mails in the same manner and under the same
			 conditions as other departments and agencies of the United States.</text>
				</paragraph>
      </subsection>
    </section>
    <section id="id5BBFFA2944B34E19BD46B8142A04FA3F">
      <enum>9.</enum>
      <header>Prize payments
			 for medical innovation</header>
			<subsection id="id9D2AE6D3FF96404A80D1A36C391DD05F">
        <enum>(a)</enum>
        <header>Award</header>
        <text>For
			 fiscal year 2015, and each subsequent fiscal year, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall award to
			 persons described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:9/ss:b" entity-type="act">subsection (b)</cato:entity-ref> prize payments for medical innovation
			 relating to a drug, a biological product, or a new manufacturing process for a
			 drug or biological product.</text>
			</subsection>
      <subsection id="id843C2BC1E4114596A3C1E36255503CFD">
        <enum>(b)</enum>
        <header>Eligibility</header>
        <text>To
			 be eligible to receive a prize payment under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:9/ss:a" entity-type="act">subsection (a)</cato:entity-ref> for medical
			 innovation relating to a drug, a biological product, or a manufacturing
			 process, a person shall be—</text>
				<paragraph id="IDeffb8e30127849989c6a0532be3a5d50">
          <enum>(1)</enum>
          <text>in the case of a
			 drug or biological product, the first person to receive market clearance with
			 respect to the drug or biological product;</text>
				</paragraph>
        <paragraph id="ID3b81b6e86b204f70b51ea26d9a555079">
          <enum>(2)</enum>
          <text>in the case of a
			 manufacturing process, the holder of the patent with respect to such process;
			 or</text>
				</paragraph>
        <paragraph id="ID25ab9f320b73417b8e933d274aca74b2">
          <enum>(3)</enum>
          <text>in the case of
			 open source contributions, the persons or communities that openly shared
			 knowledge, data, materials, and technology on a royalty-free and
			 nondiscriminatory basis.</text>
				</paragraph>
      </subsection>
      <subsection id="idAEAAB930D4C2422F9DF686408555F01D">
        <enum>(c)</enum>
        <header>Criteria</header>
        <text>The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall, by regulation, establish criteria for the selection of recipients,
			 and for determining the amount, of prize payments under this section. Such
			 criteria shall include consideration of the following:</text>
				<paragraph id="ID529a730c4a774da9b1e56e33adc3a729">
          <enum>(1)</enum>
          <text>The number of
			 patients who would benefit from the drug, biological product, or manufacturing
			 process involved, including (in cases of global neglected diseases, global
			 infectious diseases, and other global public health priorities) the number of
			 non-United States patients.</text>
				</paragraph>
        <paragraph id="IDf3eb247158e64fccb2e051e3c7506417">
          <enum>(2)</enum>
          <text>The incremental
			 therapeutic benefit of the drug, biological product, or manufacturing process
			 involved as compared to existing drugs, biological products, and manufacturing
			 processes available to treat the same disease or condition, except that the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall provide for cases where drugs, biological products, or
			 manufacturing processes are developed at roughly the same time, so that the
			 comparison is to products that were not recently developed.</text>
				</paragraph>
        <paragraph id="ID3ecf87a2d07b491dac78fe30463c9ee0">
          <enum>(3)</enum>
          <text>The degree to
			 which the drug, biological product, or manufacturing process involved addresses
			 priority health care needs, including—</text>
					<subparagraph id="ID2258044225d14e3381a48b148e1849e9">
            <enum>(A)</enum>
            <text>current and
			 emerging global infectious diseases;</text>
					</subparagraph>
          <subparagraph id="ID65762bbb46ec45208cfa22c6d3243ad3">
            <enum>(B)</enum>
            <text>severe illnesses
			 with small client populations (such as indications for which orphan designation
			 has been granted under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref value="Federal Food, Drug, and Cosmetic Act/s:526" entity-type="act">
                  <cato:entity-ref value="Federal Food, Drug, and Cosmetic Act/s:526" entity-type="act">section 526 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>
                </cato:entity-ref>
			 (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">
                  <cato:entity-ref value="usc/21/360bb" entity-type="uscode">21 U.S.C. 360bb</cato:entity-ref>
                </external-xref>)</cato:entity>); and</text>
					</subparagraph>
          <subparagraph id="IDb1f36a8e5aef48059f13b3b8a228a51d">
            <enum>(C)</enum>
            <text>neglected
			 diseases that primarily afflict the poor in developing countries.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="id9DD863E8B34748AEA8C0CD07A302E127">
          <enum>(4)</enum>
          <text>Improved
			 efficiency of manufacturing processes for drugs or biological processes.</text>
				</paragraph>
        <paragraph id="ID1456ba951b644fcba35c62f6c21bbd55">
          <enum>(5)</enum>
          <text>The extent to
			 which knowledge, data, materials and technology that are openly shared have
			 contributed to the successful development of new products or improved processes
			 for manufacturing products.</text>
				</paragraph>
        <paragraph id="idB74B111DCAA747B1B9BDA77574C9BFD4">
          <enum>(6)</enum>
          <text>In the case of
			 antibiotics or other products for which drug resistance is a significant public
			 health problem, the expected life cycle benefits of the antibiotic or other
			 product, with appropriate adjustments that reward the conservation of the
			 resources, taking into account drug resistance that is related to use of the
			 product.</text>
				</paragraph>
        <paragraph id="id9D6BC6EF17CB4768B7312146F222829E">
          <enum>(7)</enum>
          <text>In the case of
			 products used in stockpiles for potential threats to the public health, the
			 risk adjusted benefits of stockpiling the products.</text>
				</paragraph>
      </subsection>
      <subsection id="id20131C784F8F4D46B0476C9E30B3F6FD">
        <enum>(d)</enum>
        <header>Requirements</header>
        <text>In
			 awarding prize payments under this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall comply with the
			 following:</text>
				<paragraph id="ID8c6f662098464caaa2c1eb2dae80b777">
          <enum>(1)</enum>
          <text>In cases where a
			 new drug, biological product, or manufacturing process offers an improvement
			 over an existing drug, biological product, or manufacturing process and the new
			 drug, biological product, or manufacturing process competes with or replaces
			 the existing drug, biological product, or manufacturing process, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref>
			 shall continue to make prize payments for the existing drug, biological
			 product, or manufacturing process to the degree that the new drug, biological
			 product, or manufacturing process was based on or benefitted from the
			 development of the existing drug, biological product, or manufacturing
			 process.</text>
				</paragraph>
        <paragraph id="IDa2236e0f31ad468bbada3fe077b142fc">
          <enum>(2)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> may not
			 make prize payments based on the identity of the person who manufactures,
			 distributes, sells, or uses the drug, biological product, or manufacturing
			 process involved.</text>
				</paragraph>
        <paragraph id="IDb1fa95ce80a640678e10f04e4e0c6e1f">
          <enum>(3)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> may
			 award prize payments for a drug, a biological product, or a manufacturing
			 process for not more than 10 fiscal years, regardless of the term of any
			 related patents.</text>
				</paragraph>
        <paragraph id="IDff8fa208c1334ec887931abe5c2a2822">
          <enum>(4)</enum>
          <text>For any fiscal
			 year, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> may not award a prize payment for any single drug, biological
			 product, or manufacturing process in an amount that exceeds 5 percent of the
			 total amount appropriated to the Fund for that year.</text>
				</paragraph>
        <paragraph id="ID8a5aac503fef4558acc4ecaa690675a6">
          <enum>(5)</enum>
          <text>For every drug or
			 biological product that receives market clearance, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall determine
			 whether and in what amount to award a prize payment for the drug or biological
			 product not later than the end of the fourth full calendar-year quarter
			 following the calendar-year quarter in which the drug or biological product
			 receives market clearance.</text>
				</paragraph>
      </subsection>
    </section>
    <section id="id7C82F1A8B8FD4CA08718792ABD6C039C">
      <enum>10.</enum>
      <header>Prizes for
			 priority research and development</header>
			<subsection id="id850C57440E504AFF96F4238F642F331C">
        <enum>(a)</enum>
        <header>Minimum levels
			 of funding</header>
        <text>For fiscal year 2015, and each subsequent fiscal year,
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall establish and may periodically modify minimum levels of funding
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:9" entity-type="act">section 9</cato:entity-ref> for priority research and development.</text>
			</subsection>
      <subsection id="ID5afb62e4ca914a0da15779adbc8c8188">
        <enum>(b)</enum>
        <header>Initial minimum
			 levels</header>
        <text>Of the amount appropriated to the Fund for a fiscal year,
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall use (subject to the establishment or modification of an
			 applicable minimum level of funding under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:10/ss:a" entity-type="act">subsection (a)</cato:entity-ref>) not less than—</text>
				<paragraph id="ID070d58dd7ad34161a84f9176da4a41d3">
          <enum>(1)</enum>
          <text>4 percent of such
			 amount for global neglected diseases;</text>
				</paragraph>
        <paragraph id="ID216cab91f7234e6b90b64fe87b7e2a1d">
          <enum>(2)</enum>
          <text>10 percent of
			 such amount for orphan diseases; and</text>
				</paragraph>
        <paragraph id="ID4b8bfe1fb721457b9a52a9bed1f9b7a6">
          <enum>(3)</enum>
          <text>4 percent of such
			 amount for global infectious diseases and other global public health
			 priorities, including research on AIDS, AIDS vaccines, and medicines for
			 responding to bioterrorism.</text>
				</paragraph>
      </subsection>
      <subsection id="IDbc52c29b864842c7aad2490bcbbe3947">
        <enum>(c)</enum>
        <header>Public input;
			 recommendations</header>
        <text>The advisory committee on research and
			 development priorities (established pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:8/ss:b/p:3" entity-type="act">section 8(b)(3)</cato:entity-ref>) shall—</text>
				<paragraph id="ID112258060783406985f76ad36e78de16">
          <enum>(1)</enum>
          <text>solicit public
			 input on research and development priorities; and</text>
				</paragraph>
        <paragraph id="ID80095fe4a5714fa1870f78642962da38">
          <enum>(2)</enum>
          <text>periodically
			 recommend to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> modifications in the minimum levels of funding for
			 prizes for priority research and development under this section.</text>
				</paragraph>
      </subsection>
      <subsection id="ID5a10e8716b894f6181ae1bb976fe1392">
        <enum>(d)</enum>
        <header>Procedures</header>
        <text>The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Board of Trustees for the Fund for Medical Innovation Prizes" entity-type="federal-body">Board</cato:entity-ref> shall adopt procedures to establish and periodically modify minimum
			 levels of funding under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" proposed="true" value="Medical Innovation Prize Fund Act/s:9" entity-type="act">section 9</cato:entity-ref> for priority research and development.</text>
			</subsection>
    </section>
    <section id="idADDD257E113E46A3839F50EDAB9BAA0D">
      <enum>11.</enum>
      <header>Open source
			 dividend prizes</header>
			<subsection id="idB5D926D2E25449C086149428E908C61D">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text>In order to induce greater access and the open sharing of
			 knowledge, data, materials and technology, at least 5 percent of the prize
			 payments from the Fund shall be dedicated to Open Source Dividend
			 prizes.</text>
			</subsection>
      <subsection id="ID301816fbe6e941498ffd75a4196d2716">
        <enum>(b)</enum>
        <header>Procedures</header>
				<paragraph id="id2518C71E7AAE4C4686259FC7DEB211B7">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board of Trustees</cato:entity-ref> shall adopt procedures for the
			 allocation of Open Source Dividend prizes. Such procedures shall—</text>
					<subparagraph id="ID0b7afc7e047e40918c4fc71826c79fd7">
            <enum>(A)</enum>
            <text>be fully
			 transparent regarding the process for evaluating the value of open sharing of
			 knowledge, data, materials, and technology;</text>
					</subparagraph>
          <subparagraph id="ID499f0aa6bbd34d99a7062ee3f1183535">
            <enum>(B)</enum>
            <text>reward the open,
			 nondiscriminatory and royalty-free sharing of knowledge, data, materials, and
			 technology that has contributed to the development of the new drugs, biological
			 products, or manufacturing processes that are rewarded under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:9" proposed="true">sections 9</cato:entity-ref> and
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:10" proposed="true">10</cato:entity-ref>;</text>
					</subparagraph>
          <subparagraph id="ID7a63de3ccd8d4b6d8b2c3d0459722ade">
            <enum>(C)</enum>
            <text>in the case of
			 rewards for contributing to the development of new drugs, biological products,
			 or manufacturing processes rewarded under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:9" proposed="true">sections 9</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:10" proposed="true">10</cato:entity-ref>, provide for a
			 time-limited period of nominations for persons or communities whose
			 contributions were considered useful, including the evidence to support such
			 nominations to describe the significance of the contribution; and</text>
					</subparagraph>
          <subparagraph id="ID093ae7aae63848ec95136d5ca4efb555">
            <enum>(D)</enum>
            <text>provide for rules
			 and procedures to protect against conflicts of interest.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="idADA372C1F6214C3D80810A44071B2093">
          <enum>(2)</enum>
          <header>Public
			 availability of nominations</header>
          <text>The nominations described in
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:11/ss:b/p:1/sp:C" proposed="true">paragraph (1)(C)</cato:entity-ref>, and the evidence supporting such nominations, shall be
			 public. The public shall be allowed to provide commentary and additional
			 evidence on such nominations before awards are made.</text>
				</paragraph>
      </subsection>
    </section>
    <section id="idE50F415E58D44AC99C3413D17941FF82">
      <enum>12.</enum>
      <header>Competitive
			 intermediaries for funding interim technologies</header>
			<subsection commented="no" id="idA3689D4B28534412B5310FA49BA5BA08">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board of Trustees</cato:entity-ref> may authorize multiple nonprofit
			 intermediaries to reward projects for interim research and development of
			 products, or for open source dividend prizes. Such intermediaries shall compete
			 for funding from non-Federal entities that co-fund the Fund.</text>
			</subsection>
      <subsection commented="no" id="IDed9be2a0261d447bb63099affa9481cc">
        <enum>(b)</enum>
        <header>Availability</header>
        <text>Prizes
			 awarded by competitive intermediaries shall be available to persons or
			 communities that provide open, nondiscriminatory and royalty-free licenses to
			 relevant intellectual property rights.</text>
			</subsection>
      <subsection commented="no" id="IDd66521a995c3497f9a09647ffa1589f3">
        <enum>(c)</enum>
        <header>Rules</header>
        <text>The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board of Trustees</cato:entity-ref> shall adopt rules to ensure the transparency and
			 accountability of any entities authorized to act as competitive intermediaries
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:12/ss:a" proposed="true">subsection (a)</cato:entity-ref>.</text>
			</subsection>
    </section>
    <section id="id080A4D075E40426583F8651FF6EFEA89">
      <enum>13.</enum>
      <header>Special
			 transition rules</header>
			<subsection id="id01A06F1BC24A4851B50B8ED736E88291">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text>A drug or biological product that is on the market on
			 October 1, 2014, shall remain eligible for prize payments for not more than 10
			 fiscal years, consistent with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:9/ss:d/p:3" proposed="true">section 9(d)(3)</cato:entity-ref>.</text>
			</subsection>
      <subsection id="id7EDAEBCBE9CD46F29CE9B66471882C96">
        <enum>(b)</enum>
        <header>Determination
			 of value</header>
        <text>In determining the amount of a prize payment for a drug
			 or biological product described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:13/ss:a" proposed="true">subsection (a)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board</cato:entity-ref> shall calculate
			 the incremental value of the drug or biological product as of the date on which
			 the drug or biological product was first introduced in the market.</text>
			</subsection>
      <subsection id="id5D48DE904249462CB1CF2FF7D30B2045">
        <enum>(c)</enum>
        <header>Maximum
			 amount</header>
        <text>With respect to drugs and biological products described in
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:13/ss:a" proposed="true">subsection (a)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board</cato:entity-ref> may award—</text>
				<paragraph id="IDfec260897a3c42699f8b7f061e3054a7">
          <enum>(1)</enum>
          <text>of the amount
			 appropriated to the Fund for fiscal year 2015, not more than 90 percent of such
			 amount; and</text>
				</paragraph>
        <paragraph id="IDe888c1a657d84ae3aad0ced297c307cc">
          <enum>(2)</enum>
          <text>of the amount
			 appropriated to the Fund for each of the succeeding 9 fiscal years, not more
			 than a percentage of such amount that is equal to 9 percent less the percentage
			 applicable to the preceding fiscal year under this subsection.</text>
				</paragraph>
      </subsection>
    </section>
    <section id="idF3882A5CCECD4AF8BCFF08F58D9D4752">
      <enum>14.</enum>
      <header>Arbitration</header>
      <text display-inline="no-display-inline">In the case of a drug that is on the market
			 on October 1, 2014, and subject to patents owned by a party other than the
			 person who first received market clearance for the drug, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board</cato:entity-ref> shall
			 establish an arbitration procedure to determine an equitable division of any
			 prize payments under this Act among the patent owners and the person who first
			 received market clearance for the drug.</text>
		</section>
    <section id="id5D5A9F33D36E4165BA91B4BD332E04DA">
      <enum>15.</enum>
      <header>Annual audits
			 by GAO</header>
			<subsection id="idC1F70C8E79494997B5F15B563BA19EF5">
        <enum>(a)</enum>
        <header>Audits</header>
        <text>The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General of the United States</cato:entity-ref> shall conduct an audit of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board</cato:entity-ref>
			 each fiscal year to determine the effectiveness of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board</cato:entity-ref>—</text>
				<paragraph id="IDe2cdb2f9e3704508a0859258feaf4404">
          <enum>(1)</enum>
          <text>in bringing to
			 market drugs, vaccines and other biological products, and new manufacturing
			 processes for medicines in a cost-effective manner; and</text>
				</paragraph>
        <paragraph id="IDd9fec3171f0a4bc991e798d10fd1ef05">
          <enum>(2)</enum>
          <text>in addressing
			 society's medical needs, including global neglected diseases that afflict
			 primarily the poor in developing countries, indications for which orphan
			 designation has been granted under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:526">section 526 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/360bb">
                <cato:entity-ref entity-type="uscode" value="usc/21/360bb">21 U.S.C. 360bb</cato:entity-ref>
              </external-xref>)</cato:entity>, and global infectious diseases and other global
			 public health priorities.</text>
				</paragraph>
      </subsection>
      <subsection id="ID8bfc62bfe63c4e76a6d2b56c4e94a1c8">
        <enum>(b)</enum>
        <header>Reports</header>
        <text>The
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Comptroller General of the United States</cato:entity-ref> shall submit a report to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref>
			 each fiscal year on the results of each audit conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:15/ss:a" proposed="true">subsection
			 (a)</cato:entity-ref>.</text>
			</subsection>
    </section>
    <section id="id0377381339E34A769912175409CBFD46">
      <enum>16.</enum>
      <header>Report to
			 Congress</header>
      <text display-inline="no-display-inline">Not later than 1 year
			 after the date of the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board</cato:entity-ref> shall submit to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref>
			 a report containing the findings, conclusions, and recommendations of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board</cato:entity-ref>
			 concerning the implementation and administration of this Act, including
			 recommendations for such legislative and administrative action as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Board of Trustees for the Fund for Medical Innovation Prizes" proposed="true">Board</cato:entity-ref>
			 determines to be appropriate.</text>
		</section>
    <section id="id16A750256D414BDF9805CD6DF0B9823B">
      <enum>17.</enum>
      <header>Funding</header>
			<subsection id="id9F5FD9193DAD464F83CCA8BA36D076E9">
        <enum>(a)</enum>
        <header>Appropriations</header>
				<paragraph id="idC05C28EE1A924FE79D62F374750010EC">
          <enum>(1)</enum>
          <header>Start-up
			 costs</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
              <cato:funds-and-year amount="indefinite" year="2015">For fiscal year 2015, there are authorized to be
			 appropriated to the Fund, such sums as may be necessary</cato:funds-and-year> <cato:property name="purpose">to carry out <cato:entity-ref entity-type="act" value="Medical Innovation Prize Fund Act" proposed="true">this
			 Act</cato:entity-ref>
              </cato:property>.</cato:entity>
          </text>
				</paragraph>
        <paragraph id="ID276e2d0aa8c14e24b71581179cddf6b6">
          <enum>(2)</enum>
          <header>Program
			 implementation</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">For fiscal year 2015 and each subsequent fiscal
			 year, there is appropriated to the Fund, out of any funds in the Treasury not
			 otherwise appropriated, <cato:funds-and-year amount="indefinite" year="2015,..">an amount equal to the amount that is .55 percent of
			 the gross domestic product of the United States for the preceding fiscal year</cato:funds-and-year>
			 (as such amount is determined by the <cato:entity-ref entity-type="federal-body">Secretary of Commerce</cato:entity-ref>).</cato:entity>
          </text>
				</paragraph>
      </subsection>
      <subsection id="idC493C3622C4C45BEB0C8123772116D1D">
        <enum>(b)</enum>
        <header>Availability</header>
        <text>Funds
			 appropriated to the Fund for a fiscal year shall remain available for
			 expenditure in accordance with this Act until the end of the 3-year period
			 beginning on October 1 of such fiscal year. Any such funds that are unexpended
			 at the end of such period shall revert to the Treasury.</text>
			</subsection>
    </section>
    <section commented="no" id="id208627C53AB4429F9C431FB9E9737BAD">
      <enum>18.</enum>
      <header>Imposition of
			 annual fee on health insurance providers</header>
			<subsection commented="no" id="id5509F27D7DD54427B65E2FC1D1163010">
        <enum>(a)</enum>
        <header>Imposition of
			 fee</header>
				<paragraph commented="no" id="id9276A6EA61914839A334ECB1AF479BCF">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text>Each covered entity engaged in the business of providing
			 health insurance shall pay to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than the annual payment
			 date of each calendar year beginning after 2014 a fee in an amount determined
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:18/ss:b" proposed="true">subsection (b)</cato:entity-ref>.</text>
				</paragraph>
        <paragraph commented="no" id="id8A2AFACEE31341DBA9EA76F3C15F78ED">
          <enum>(2)</enum>
          <header>Annual payment
			 date</header>
          <text>For purposes of this section, the term <term>annual payment
			 date</term> means, with respect to any calendar year, a date determined by the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, which in no event, may be later than September 30 of such calendar
			 year.</text>
				</paragraph>
      </subsection>
      <subsection commented="no" id="id37D1A95AC77E4A12986CF377CCCE1D78">
        <enum>(b)</enum>
        <header>Determination
			 of fee amount</header>
        <text>With respect to each covered entity, the fee under
			 this section for any calendar year shall be equal to the amount determined
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:17/ss:a/p:2" proposed="true">section 17(a)(2)</cato:entity-ref>, multiplied by the ratio of the covered entity’s net
			 premiums written with respect to health insurance for any United States health
			 risk taken into account under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:18/ss:c" proposed="true">subsection (c)</cato:entity-ref> during the preceding calendar
			 year, to—</text>
				<paragraph commented="no" id="idE94EAE0C86AA43B5A24B8FBCB71E8BF6">
          <enum>(1)</enum>
          <text>the sum of net
			 premiums for all covered entities; and</text>
				</paragraph>
        <paragraph commented="no" id="id5B83782182A34105865E24A1CFF8F80F">
          <enum>(2)</enum>
          <text>all Federal
			 outlays on health insurance or reimbursement of health care costs, excluding
			 the costs of long term care.</text>
				</paragraph>
      </subsection>
      <subsection id="IDd51fefb2e1384e89b050dc895979b22d">
        <enum>(c)</enum>
        <header>Amounts taken
			 into account</header>
        <text>For purposes of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medical Innovation Prize Fund Act/s:18/ss:b" proposed="true">paragraph (b)</cato:entity-ref>, the net premiums
			 written with respect to health insurance for any United States health risk that
			 are taken into account during any calendar year with respect to any covered
			 entity shall be determined as follows:</text>
				<paragraph id="idE11E8A5787AC4FD4A214B83380C0F0F2">
          <enum>(1)</enum>
          <text>With respect to a
			 covered entity’s net premiums written during the calendar year that are not
			 more than $25,000,000, the percentage of net premiums written that are taken
			 into account is 0 percent.</text>
				</paragraph>
        <paragraph id="idB938B34EF79D401B8D3FE259B4D724C3">
          <enum>(2)</enum>
          <text>With respect to a
			 covered entity’s net premiums written during the calendar year that are more
			 than $25,000,000 but less than $50,000,000, the percentage of net premiums
			 written that are taken into account is 50 percent.</text>
				</paragraph>
        <paragraph id="id4D0162576CEB4DF1B1F9A5FDD1962879">
          <enum>(3)</enum>
          <text>With respect to a
			 covered entity’s net premiums written during the calendar year that are
			 $50,000,000 or more, the percentage of net premiums written that are taken into
			 account is 100 percent.</text>
				</paragraph>
      </subsection>
      <subsection id="idC5B572237568443390CACF72F2608F4E">
        <enum>(d)</enum>
        <header>Covered
			 entity</header>
				<paragraph id="IDd75887a7ce3f4b14be589c3da784b734">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text>For purposes of this section, the term <term>covered
			 entity</term> means any entity which provides health insurance for any United
			 States health risk.</text>
				</paragraph>
        <paragraph id="ID2e06316d8f494c8eb2f20252d9d10e7d">
          <enum>(2)</enum>
          <header>Exclusion</header>
          <text>Such
			 term does not include any governmental entity.</text>
				</paragraph>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>